References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17; 364(11):1046–1060.
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA A Cancer J Clin. 2021 Jan;71(1):7–33.
- Myeloma - Cancer Stat Facts [Internet]. SEER. [ cited Available from 2022 Feb 16: https://seer.cancer.gov/statfacts/html/mulmy.html.
- National Comprehensive Cancer Network. Multiple myeloma (version 4.2022), www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 2022 Feb 16).
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–2275.
- Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017 Nov;31(11):2443–2448.
- Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (Bcma) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022 Jun;28(4):960–968.
- Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25 384(8):705–716.
- Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24 398(10297):314–324.
- Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019 Aug 22 381(8):727–738.
- Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207–221.
- Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021 Mar 1;39(7):757–767.